We recommend that further study be required to establish safety and confirm efficacy. In our patients, tofacitinib successfully alleviated AU in the absence of significant adverse side-effects. Axillary hair regrowth and isolated leg hair was noted by 8 months. By 4 months into treatment, significant scalp regrowth was observed as well as eyelash, eyebrow and beard regrowth. In the second patient, a noticeable increase in scalp hair was present just 1 month into treatment. In addition, eyelashes and eyebrows were established. By 8 months of treatment, scalp hair continued to grow longer and thicker. By 6 months of treatment, hair growth was apparent throughout the entire body. In the first patient, beard growth was significant by 3 months of treatment. Two patients diagnosed with long-term AU were prescribed tofacitinib citrate at a dosage of 5 mg twice daily and observed for eight months. Our study aims to provide evidence for the effectiveness of tofacitinib in the treatment of AU. The targeted kinase inhibitor tofacitinib, in current use for treatment of other immune diseases, has been hypothesized as a viable option for AA, AT and AU therapy and a few case reports support this. For AT and AU a reliable treatment has remained elusive. Initially patchy and often self-limited, severe hair loss forms include the complete loss of scalp hair or alopecia totalis (AT) and complete loss of all hair or alopecia universalis (AU). Autoimmune-triggered non-scarring hair loss is a feature of alopecia areata (AA).
0 kommentar(er)
